Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.

MLA

Hatcher, John M., et al. “Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.” ACS Medicinal Chemistry Letters, vol. 11, no. 11, Oct. 2020, pp. 2238–43. EBSCOhost, https://doi.org/10.1021/acsmedchemlett.0c00378.

APA

Hatcher, J. M., Yang, G., Wang, L., Ficarro, S. B., Buhrlage, S., Wu, H., Marto, J. A., Treon, S. P., & Gray, N. S. (2020). Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Medicinal Chemistry Letters, 11(11), 2238–2243. https://doi.org/10.1021/acsmedchemlett.0c00378

Chicago

Hatcher, John M, Guang Yang, Li Wang, Scott B Ficarro, Sara Buhrlage, Hao Wu, Jarrod A Marto, Steven P Treon, and Nathanael S Gray. 2020. “Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.” ACS Medicinal Chemistry Letters 11 (11): 2238–43. doi:10.1021/acsmedchemlett.0c00378.